Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-400 Combinations in Previously Treated Unresectable Metastatic Colorectal Cancer
2023-505110-14-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised trial of telisotuzumab adizutecan in colorectal cancer (CRC) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Objective Response and Progression-free Survival. Planned start Aug 2024; status: authorised.
02
Drugs
telisotuzumab adizutecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-505110-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505110-14-00.